Main Uses of Trusopt

Trusopt is an ophthalmic solution primarily indicated for the reduction of elevated intraocular pressure. It is used in patients who have specific ocular conditions where the fluid pressure within the eye is higher than the normal physiological range.

Open-Angle Glaucoma

The medication is frequently prescribed for the treatment of open-angle glaucoma. In this condition, the drainage angle of the eye remains open, but the fluid (aqueous humor) does not drain properly, leading to a gradual increase in pressure. If left unmanaged, this elevated pressure can cause progressive damage to the optic nerve.

Ocular Hypertension

Trusopt is also used for patients diagnosed with ocular hypertension. This term describes a situation where the pressure inside the eye is higher than normal, but the patient does not yet show signs of optic nerve damage or vision loss. Lowering the pressure in these cases is often a preventive measure to reduce the risk of developing glaucoma.

Benefits and Mechanism of Action

Trusopt belongs to a class of medications known as carbonic anhydrase inhibitors. Its therapeutic benefits are derived from its ability to regulate fluid production within the eye.

• Reduction of Aqueous Humor Production: The active ingredient, dorzolamide, inhibits the enzyme carbonic anhydrase in the ciliary processes of the eye. This inhibition slows down the production of aqueous humor.
• Pressure Management: By decreasing the inflow of fluid, the medication helps to lower the overall internal pressure of the eye.
• Support for Long-Term Eye Health: Consistently maintaining intraocular pressure within a target range is the primary method for slowing the progression of glaucoma-related vision impairment and protecting the integrity of the optic nerve.

Eligibility and Restrictions for Трусопт (Dorzolamide)

Трусопт is officially approved for use in adult patients and pediatric patients aged 2 years and older who require treatment for elevated intraocular pressure. Eligibility for this medicine is strictly defined by regulatory guidelines, primarily based on patient health status and age.

Absolute Contraindications

The medicine must not be used by certain populations:

• Patients with documented hypersensitivity to Dorzolamide hydrochloride or any formulation component.
• Individuals with severe renal impairment (creatinine clearance less than 30 mL/min).
• Patients diagnosed with hyperchloraemic acidosis.

Special Population Constraints

Use of Трусопт is limited or requires special consideration in several groups:

• Concurrent Therapy: Concomitant use with an oral carbonic anhydrase inhibitor is not recommended due to potential additive systemic effects.
• Organ Function: Use is advised with caution in patients with hepatic impairment (as studies are lacking). Patients with pre-existing corneal defects also require caution.
• Age and Development: Use is not established for infants under 2 years of age.
• Reproductive Status: The medicine should not be used during pregnancy, and treatment is not recommended for breastfeeding mothers.

Interactions with other medicines and products

The topical ophthalmic solution Трусопт (Dorzolamide) is systemically absorbed, establishing the basis for its documented pharmacodynamic and clearance-related restrictions outlined in regulatory information.

---

Documented Pharmacodynamic Interactions and Restrictions

Interacting Product/Class	Official Regulatory Statement
Oral Carbonic Anhydrase Inhibitors (CAIs)	Co-administration is not recommended due to the potential for an additive systemic effect on carbonic anhydrase inhibition.
High-Dose Salicylate Therapy	Potential exists for an interaction leading to toxicity, based on risks documented with systemic CAIs.

---

Procedural and Clearance-Based Constraints

Constraint Type	Official Regulatory Statement
Administration Timing Rule	If co-administering with other topical ophthalmic drugs, the medications must be administered at least five minutes apart.
Renal Clearance Restriction	Use is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 ml/min) due to the risk of systemic accumulation and reduced clearance.
Hepatic Function	Use with caution is advised in patients with hepatic impairment, as the drug has not been studied in this population.

In clinical studies, Трусопт was used concomitantly with various systemic medications, including diuretics and non-steroidal anti-inflammatory agents, without evidence of adverse interactions. No specific interactions with food, alcohol, or herbal products are explicitly documented in the official prescribing information.

Enzyme Inhibition in the Ciliary Body

This domain covers the drug's primary action: its role as a selective inhibitor of the enzyme Carbonic Anhydrase Isozyme II (CA-II), which is concentrated in the ciliary processes. This inhibition directly blocks the enzyme-mediated chemical reaction necessary for fluid secretion.

---

Modulation of Aqueous Humor Dynamics

This mechanistic domain explains the subsequent molecular cascade. By inhibiting CA-II, the formation of bicarbonate ions is disrupted, leading to a reduction in the transport of water and ions across the ciliary epithelium. This fundamentally alters the rate of aqueous humor secretion.

---

Reduction of Intraocular Pressure

This final domain describes the observable physiological effect that emerges from the mechanistic cascade. The reduced rate of aqueous humor production leads directly to a new, lower pressure equilibrium inside the eyeball, resulting in the drug's core physiological action: a decrease in intraocular pressure (IOP).

Трусопт (Dorzolamide Ophthalmic Solution 2%) is intended for topical ophthalmic use via administration directly into the affected eye(s). The concentration is established as a 2% solution, which is the standardized preparation for use.

The administration schedule depends on whether the medication is used alone or as part of a combined regimen. For monotherapy, the adult dose is one drop applied three times daily (T.I.D.). In cases of adjunctive therapy used alongside an ophthalmic beta-blocker, the frequency is one drop two times daily (B.I.D.). Proper application involves specific procedural conditions. If multiple topical eye medications are being used, the products should be instilled at least five minutes apart. To limit systemic absorption, light pressure can be applied to the nasolacrimal duct or the eyelids can be closed gently for two minutes immediately following instillation.

Usage is subject to specific procedural and population constraints. Patients using soft contact lenses must remove the lenses prior to administration and wait 15 minutes before reinsertion. In the presence of severe renal impairment, characterized by a creatinine clearance of less than 30 mL/min, the medication is not recommended because of its primary route of excretion. If a dose is missed, it should be administered as soon as remembered, unless it is almost time for the next scheduled dose; in that instance, the missed dose should be skipped to maintain the regular schedule.

Research evidence / Overview of studies

The research literature on Trusopt (dorzolamide) consists primarily of randomized, controlled trials (RCTs) and post-marketing observational studies. The majority of research has studied to assess potential effects on clinical outcomes in adults with elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension.

The key trials generally compared dorzolamide against a placebo or, in some cases, against an established standard-of-care treatment over a 12- to 24-week period.

Key Efficacy Findings

Studies evaluated potential for a reduction in IOP, a primary measure for managing glaucoma. Primary endpoints included patient-reported outcome measures (PROMs) and clinician-assessed scores. Research explored whether the treatment was associated with a reduction in IOP at various time points, with findings varying across subpopulations.

The study designs assessed the incidence of reduction in overall IOP levels. For example, a Phase 3 trial (N=450) indicated an improvement in the average IOP level compared to the placebo group.

Safety and Tolerability Profile

This drug class has been the subject of several long-term safety extension studies. Study data described the incidence of adverse events across the studied population, with the most commonly reported events including burning, stinging, or discomfort in the eye, and taste perversion. The incidence of serious adverse events was described in study reports.

Some studies incorporated comparisons against other standard-of-care options and reported on the differential rates of treatment discontinuation due to adverse events. Overall, the data presented a profile of adverse events consistent with observations for this drug class.

Key Studies & References

1. Clinical effectiveness and safety of brimonidine (0.2%) versus Dorzolamide (2.0%) in primary open angle
2. Glaucoma: diagnosis and management - NICE Guideline NG81 (Used for context on treatment steps and comparisons)

Common questions about Трусопт (FAQ)

Q: What is the role of Трусопт (Trusopt) in treating glaucoma?

According to the official product information, Трусопт is an eye drop solution that contains dorzolamide. It is used to lower elevated intraocular pressure (IOP) in conditions like ocular hypertension and open-angle glaucoma. It works by reducing the production of fluid within the eye, which helps to lower eye pressure in these conditions, according to official documents.

Q: How does Трусопт (dorzolamide) work to treat high eye pressure?

Трусопт contains the active substance dorzolamide, which belongs to a group of medicines called carbonic anhydrase inhibitors. This substance works to reduce the production of aqueous humor, which is the fluid inside the eye. By lowering the rate of fluid production, it reduces the pressure buildup within the eye, helping to manage the high eye pressure associated with glaucoma.

Q: Is Трусопт safe to use for patients with severe kidney problems?

Regulatory documents state that caution is advised for patients with severe renal impairment (severe kidney problems). Because the medicine and its active metabolite are primarily excreted by the kidneys, its use has not been studied in these patients. Official documents emphasize that patients with severe renal impairment should always consult their prescribing doctor.

Q: Can I use soft contact lenses while being treated with Трусопт?

The official product information advises that soft contact lenses should be removed before applying the Трусопт eye drops. They should not be reinserted until at least 15 minutes after the drops have been administered. This is because the preservative in the solution, benzalkonium chloride, can be absorbed by soft lenses and may cause irritation or discoloration.

Q: What is the active ingredient in Трусопт?

The primary active ingredient in Трусопт is a medication called dorzolamide. This substance is formulated as an eye drop solution and works as a carbonic anhydrase inhibitor to lower the pressure inside the eye.

Q: How should I store Трусопт eye drops?

According to the official information, Трусопт should be stored out of the reach of children and kept at a temperature below 30°C. It is important not to use the medicine after the expiration date printed on the carton. The dropper bottle must also be kept tightly closed to prevent contamination.

Storage and Disposal Requirements for TRUSOPT (Dorzolamide Hydrochloride)

TRUSOPT ophthalmic solution must be stored at a controlled room temperature of 15 C to 25 C (59 F to 77 F). It is mandatory to keep the product protected from light and it must not be frozen or stored above 30 C. The medicine should always be kept out of the sight and reach of children.

---

Stability and Handling

• Multi-Dose Bottle: Any remaining solution must be discarded 28 days after first opening.
• Single-Dose Container (Preservative-Free): The solution must be used immediately after opening and any remaining contents discarded to maintain sterility. Units remaining in the foil sachet must be used within 15 days of opening the sachet.

---

Official Disposal

Unused or expired TRUSOPT must be disposed of according to local regulatory requirements for medicinal products and should not be thrown into wastewater or household trash.